ARCHIVES

Adding Topotecan To Standard Treatment Doesn’t Improve Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 33 No. 10 | October 29, 2010

Download PDF Visit The Full Archive

Related Articles

Brigham & Women’s Suspends Controversial Morcellation Study As Apparent “Difference of Opinion” with FDA Comes to Light

November 26, 2014

Cancer Centers Branch To Be ‘More Proactive,’ Kimes Tells NCAB

January 5, 1990

Case Study: The Post-Surgical Treatment Of A Child With Medulloblastoma At The Burzynski Clinic

September 25, 1998

Loehrer To Direct IU Simon Cancer Center

March 5, 2010

NCCN Admits Two New Member Institutions

March 22, 2013

Reports On Nutrition & Cancer Show Needs For More Clinical Studies

September 5, 1975